Takeda is considering submitting a bid for British drugmaker Shire, to expand its U.S. presence.
The European Commission approved Takeda and TiGenix’s perianal fistulas drug Alofisel.
Protagonist Therapeutics discontinued the phase 2b study of its ulcerative colitis drug, PTG-100, after the trial was deemed too futile to continue.
Pfizer will fund the American Gastroenterological Association’s Young Investigator Pilot Research Awards in Inflammatory Bowel Disease.
AbbVie’s Vice President of U.S. Immunology Mark Stenhouse is joining Exact Sciences as president of the company’s Cologuard product, effective April 2.
More articles on gastroenterology:
Readers push back on ‘sensationalized’ story misrepresenting ASC safety — 5 insights
3 ways ASCs can capitalize on the transition to outpatient care
Drugmaker paid roughly $550K to lobby for ASC, outpatient reimbursement status
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
